Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 7
Treatment-assignment count: 0
Stratification count: 0
Drug Development Ahead Of Cdx Context
BRAF V600E
melanoma · Small Molecule Inhibitor
BRAF V600E is flagged as drug development ahead of cdx context because public trials show inclusion required evidence in 8 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 0
Common snippets: None extracted
Threshold label: Low
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT02314143 | https://clinicaltrials.gov/study/NCT01902173 | https://clinicaltrials.gov/study/NCT01835184 | https://clinicaltrials.gov/study/NCT01519427 | https://clinicaltrials.gov/study/NCT01072175 | https://clinicaltrials.gov/study/NCT02723006 | https://clinicaltrials.gov/study/NCT02645149 | https://clinicaltrials.gov/study/NCT04253080